tirzepatide surmount 1 SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 π πSustained weight loss of 22.9% or an average 54lbs over 3 years π½94% reduction in risk of progression to diabetes. Number surmount-1 trial tirzepatide obesity without
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14

01200-X/asset/f2ef2727-f32c-4146-a724-f0b9312e4d9f/main.assets/gr1_lrg.jpg)



























